- Home
- REPL vs LAB Comparison
REPL vs LAB Comparison
Compare REPL & LAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REPL
- LAB
- Stock Information
- Founded
- REPL 2015
- LAB 1999
- Country
- REPL United States
- LAB United States
- Employees
- REPL N/A
- LAB N/A
- Industry
- REPL Biotechnology: Pharmaceutical Preparations
- LAB Biotechnology: Laboratory Analytical Instruments
- Sector
- REPL Health Care
- LAB Industrials
- Exchange
- REPL Nasdaq
- LAB Nasdaq
- Market Cap
- REPL 547.0M
- LAB 473.2M
- IPO Year
- REPL 2018
- LAB 2011
- Fundamental
- Price
- REPL $5.71
- LAB $1.35
- Analyst Decision
- REPL Hold
- LAB Buy
- Analyst Count
- REPL 9
- LAB 2
- Target Price
- REPL $7.00
- LAB $2.50
- AVG Volume (30 Days)
- REPL 2.1M
- LAB 1.1M
- Earning Date
- REPL 11-11-2025
- LAB 10-29-2025
- Dividend Yield
- REPL N/A
- LAB N/A
- EPS Growth
- REPL N/A
- LAB N/A
- EPS
- REPL N/A
- LAB N/A
- Revenue
- REPL N/A
- LAB $172,271,000.00
- Revenue This Year
- REPL N/A
- LAB N/A
- Revenue Next Year
- REPL $408.25
- LAB N/A
- P/E Ratio
- REPL N/A
- LAB N/A
- Revenue Growth
- REPL N/A
- LAB 76.33
- 52 Week Low
- REPL $2.68
- LAB $0.92
- 52 Week High
- REPL $17.00
- LAB $2.32
- Technical
- Relative Strength Index (RSI)
- REPL 46.92
- LAB 55.30
- Support Level
- REPL $5.60
- LAB $1.27
- Resistance Level
- REPL $6.15
- LAB $1.41
- Average True Range (ATR)
- REPL 0.33
- LAB 0.08
- MACD
- REPL 0.06
- LAB 0.01
- Stochastic Oscillator
- REPL 32.48
- LAB 68.18
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.
About LAB Standard BioTools Inc.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.